Get it to United States within 10 working days with standard delivery.

Fast delivery to United States

Easy Returns & Exchanges

Ask About This Product

Condition : New


From UAE

To United States

in 5-10 days


YULAREB (belantamab mafodotin-blmf) is a medication used to treat relapsed or refractory multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here’s an overview: Pros:
  1. Novel Mechanism of Action: YULAREB is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA), a protein found on the surface of multiple myeloma cells. It delivers a cytotoxic agent directly to the cancer cells, causing cell death.
  2. Efficacy in Relapsed or Refractory Multiple Myeloma: Clinical trials have shown that YULAREB can induce responses in patients with relapsed or refractory multiple myeloma who have received prior treatment with other therapies.
  3. Convenient Administration: YULAREB is administered by intravenous infusion once every three weeks, which may be more convenient for patients compared to daily oral medications or frequent hospital visits.
  4. Potential for Improved Outcomes: By targeting BCMA, YULAREB offers a targeted approach to treating multiple myeloma, potentially leading to improved outcomes compared to conventional chemotherapy.
  1. Side Effects: Common side effects of YULAREB may include corneal events (such as keratopathy or blurred vision), thrombocytopenia (low platelet count), and infusion-related reactions. Some side effects may be severe and require dose adjustments or discontinuation of treatment.
  2. Risk of Ocular Toxicity: YULAREB can cause ocular toxicity, including changes in vision, which may be reversible upon discontinuation of the medication. Regular ophthalmologic monitoring is recommended during treatment.
  3. Cost: YULAREB can be expensive, especially for those without adequate insurance coverage. The price can vary depending on factors such as location and insurance plan.
Price Comparison: The price of YULAREB 150 mg tablets can vary significantly depending on the country, pharmacy, and insurance coverage. In the United States, for example, the average wholesale price (AWP) for YULAREB can range from $10,000 to $12,000 per vial. However, patients may be eligible for financial assistance programs from the manufacturer or other sources to help cover the cost. Patients should discuss the potential benefits and risks of YULAREB with their healthcare provider, as well as any concerns about affordability. Close monitoring is essential to manage side effects and ensure the best treatment outcomes.
Shopping Cart